- Home
- BLTE vs ICLR Comparison
BLTE vs ICLR Comparison
Compare BLTE & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLTE | ICLR |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 7.1B |
| IPO Year | 2021 | 2001 |
Fundamental Metrics
Financial Performance| Metric | BLTE | ICLR |
|---|---|---|
| Price | $162.37 | $96.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 13 |
| Target Price | $181.14 | ★ $182.08 |
| AVG Volume (30 Days) | 164.5K | ★ 1.3M |
| Earning Date | 03-02-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $218.41 | N/A |
| P/E Ratio | ★ N/A | $12.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.00 | $66.57 |
| 52 Week High | $200.00 | $211.00 |
Technical Indicators
Market Signals| Indicator | BLTE | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 38.16 | 33.63 |
| Support Level | $148.78 | $66.57 |
| Resistance Level | $165.64 | $113.88 |
| Average True Range (ATR) | 8.78 | 4.28 |
| MACD | -2.47 | 1.53 |
| Stochastic Oscillator | 13.14 | 6.34 |
Price Performance
Historical ComparisonAbout BLTE Belite Bio Inc
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.